1 active not recruiting, 1 available, 1 completed, 1 not yet recruiting. 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Jubilant DraxImage Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab Radiation: 131I-MIBG, Dinutuximab, Vorinostat - Neuroblastoma | Phase 2 | Not yet recruiting | New Approaches to Neuroblastoma Therapy Consortium | 118 | 2026-12-31 | 2026-08-21 |
| Dose Optimization for Rubidium PET Imaging in Patients With Known or Suspected Ischemic Heart Disease Rb-82 Radioisotope - Ischemic Heart Disease | Active not recruiting | Ottawa Heart Institute Research Corporation | 48 | 2022-07-01 | 2026-05-12 | |
| A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects 131I-MIBG, 131-MIBG + Vorinostat - Neuroblastoma, Neuroectodermal Tumors | Phase 2 | Unknown | Jubilant DraxImage Inc. | 60 | 2019-10-21 | 2023-02-16 |
| Rubidium Elution System Performance Testing Coronary Artery Disease | Completed | Ottawa Heart Institute Research Corporation | 15800 | 2014-01-01 | 2018-12-24 | |
| 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study 124I-Metaiodobenzylguanidine (MIBG) (no-carrier added), 124I-MIBG (carrier added), Positron Emission Tomography (PET) /Computerized tomography (CT) - Neuroblastoma | Early Phase 1 | Terminated | Miguel Pampaloni | 10 | 2013-04-09 | 2021-05-14 |
| Expanded Access Protocol Using 131I-MIBG I-131 MIBG - Neuroblastoma, Pheochromocytoma | Available | Jubilant DraxImage Inc. | 2023-02-28 |
Neuroblastoma (4) · Coronary Artery Disease (1) · Myocardial Ischemia (1) · Neoplasms (1) · Neuroectodermal Tumors (1) · Paraganglioma (1) · Pheochromocytoma (1)
3-Iodobenzylguanidine (4) · Vorinostat (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Magnetic Resonance Spectroscopy (1) · Rubidium-82 (1) · dinutuximab (1)
United States (4) · Canada (2)
Jose Miguel Hernandez-Pampaloni, MD, PhD (1) · Katherine Matthay, MD (1) · Melda Dolan (1) · Rob S Beanlands, MD (1) · Youngho Seo, PhD (1)